Tags: EU | Switzerland | Roche | Drug | Deaths

Roche Suspends Arthritis Drug Study After Deaths

Monday, 08 Mar 2010 07:25 AM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink

Swiss pharmaceutical company Roche Group said Monday it has suspended a late-stage trial for a new rheumatoid arthritis and lupus drug after several patients died from infections.

Roche said the drug, ocrelizumab, was developed together with Biogen Idec with headquarters in Cambridge, Massachusetts.

A review found "the safety risk outweighs the benefits observed in these specific patient populations at this time" after detecting "serious and opportunistic infections, some of which were fatal," Basel-based Roche said.

It declined immediately to say how many patients died, where and when.

The company said it was still testing ocrelizumab for patients with relapsing remitting multiple sclerosis

Roche shares were down 0.6 percent at 179.60 Swiss francs ($167.54) on the Zurich exchange.

© Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web

Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 

You May Also Like
Around the Web

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved